EGFR and lung carcinoma: PD-L1-enhancing oncogenes, such as EGFR, ALK, MET, AKT, MYC, and CDK5, were not identified as hits in this study because KRAS mutations in lung cancer cell lines (H2009 and H460) could establish distinct PD-L1 regulatory axes.